Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience

G. Bonadonna, A. Santoro, A. M. Gianni, S. Viviani, S. Siena, M. Bregni, R. Zucali, F. Lombardi, V. Bonfante, L. Gianni, P. Valagussa

Research output: Contribution to journalArticle

Abstract

This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalAnnals of Oncology
Volume2
Issue numberSUPPL. 1
Publication statusPublished - 1991

Fingerprint

Anthracyclines
Hodgkin Disease
Procarbazine
Drug Therapy
Mechlorethamine
Salvage Therapy
Dacarbazine
Vinblastine
Bleomycin
Vincristine
Prednisone
Treatment Failure
Pharmaceutical Preparations
Doxorubicin
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bonadonna, G., Santoro, A., Gianni, A. M., Viviani, S., Siena, S., Bregni, M., ... Valagussa, P. (1991). Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Annals of Oncology, 2(SUPPL. 1), 9-16.

Primary and salvage chemotherapy in advanced Hodgkin's disease : The Milan Cancer Institute experience. / Bonadonna, G.; Santoro, A.; Gianni, A. M.; Viviani, S.; Siena, S.; Bregni, M.; Zucali, R.; Lombardi, F.; Bonfante, V.; Gianni, L.; Valagussa, P.

In: Annals of Oncology, Vol. 2, No. SUPPL. 1, 1991, p. 9-16.

Research output: Contribution to journalArticle

Bonadonna, G, Santoro, A, Gianni, AM, Viviani, S, Siena, S, Bregni, M, Zucali, R, Lombardi, F, Bonfante, V, Gianni, L & Valagussa, P 1991, 'Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience', Annals of Oncology, vol. 2, no. SUPPL. 1, pp. 9-16.
Bonadonna, G. ; Santoro, A. ; Gianni, A. M. ; Viviani, S. ; Siena, S. ; Bregni, M. ; Zucali, R. ; Lombardi, F. ; Bonfante, V. ; Gianni, L. ; Valagussa, P. / Primary and salvage chemotherapy in advanced Hodgkin's disease : The Milan Cancer Institute experience. In: Annals of Oncology. 1991 ; Vol. 2, No. SUPPL. 1. pp. 9-16.
@article{441f4871f7534a519d0c12d717ef363b,
title = "Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience",
abstract = "This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.",
author = "G. Bonadonna and A. Santoro and Gianni, {A. M.} and S. Viviani and S. Siena and M. Bregni and R. Zucali and F. Lombardi and V. Bonfante and L. Gianni and P. Valagussa",
year = "1991",
language = "English",
volume = "2",
pages = "9--16",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Primary and salvage chemotherapy in advanced Hodgkin's disease

T2 - The Milan Cancer Institute experience

AU - Bonadonna, G.

AU - Santoro, A.

AU - Gianni, A. M.

AU - Viviani, S.

AU - Siena, S.

AU - Bregni, M.

AU - Zucali, R.

AU - Lombardi, F.

AU - Bonfante, V.

AU - Gianni, L.

AU - Valagussa, P.

PY - 1991

Y1 - 1991

N2 - This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

AB - This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026067722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026067722&partnerID=8YFLogxK

M3 - Article

C2 - 1710489

AN - SCOPUS:0026067722

VL - 2

SP - 9

EP - 16

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -